Recorded Presentations from the NCCN 2017 Congress Webinar Series™: Lung Cancer
The goal of this educational program is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practices and healthcare settings for patients with lung cancer and those being screened for lung cancer.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with lung cancer and those being screened for lung cancer.
Following this activity, participants should be able to:
New Strategies to Improve the Accuracy of Lung Cancer Screening
- Discuss the risk assessment process used to determine whether patients are candidates for lung cancer screening.
- Evaluate and follow-up the findings of different types of nodules that may be detected on low-dose computed tomography.
- Identify when to recommend further screening, biopsy, surgical excision of nodules based on recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Lung Cancer Screening.
- Appropriately counsel patients about the risks and benefits of lung cancer screening.
What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer
- Identify the appropriate use of liquid biopsy and tissue biopsy in assessing for biomarkers in patients with metastatic non-small cell lung cancer (NSCLC).
- Describe the recommended molecular testing for patients with NSCLC and sensitizing EGFR mutations and T790M.
- Summarize the currently known mechanisms for primary and secondary resistance to erlotinib, gefitinib, and afatinib.
Immunotherapies in Lung Cancer
- Identify the new recommended immunotherapy regimens for patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- Evaluate the risks and benefits of using immune-checkpoint inhibitor therapy.
- Educate health care providers about adverse events that may occur with immunotherapy and appropriate management.
- Describe the challenges with diagnosing pneumonitis.
- Summarize the role of biomarker testing to assist with selecting the most appropriate immunotherapeutic agents for patients with metastatic NSCLC.
Sequencing Therapy for Advanced Non-Small Cell Lung Cancer
- Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ALK gene rearrangements.
- Describe sequencing of systemic therapy for patients with metastatic NSCLC and sensitizing EGFR mutations.
- Identify the subsequent therapy regimens for patients with wild-type NSCLC.
- Select the most appropriate subsequent therapy regimens for patients with advanced NSCLC who have progressed after first-line systemic therapy.
- Discuss sequencing of systemic therapy for patients with metastatic NSCLC and ROS1 gene rearrangements.
- Describe the different biomarkers for which effective targeted therapy is available for patients with metastatic NSCLC.
Managing Toxicities of Newer Agents
- Describe the spectrum of immune-related adverse events that may occur with immune-checkpoint inhibitor therapy.
- Educate patients and their caregivers about symptoms suggestive of immune-related adverse events.
- Manage immune-related adverse events associated with immune-checkpoint inhibitor therapy.
- Monitor for and manage patients who have adverse events associated with ALK inhibitors.
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.